SG10201604757RA - Dosing regimens for the treatment of fabry disease - Google Patents
Dosing regimens for the treatment of fabry diseaseInfo
- Publication number
- SG10201604757RA SG10201604757RA SG10201604757RA SG10201604757RA SG10201604757RA SG 10201604757R A SG10201604757R A SG 10201604757RA SG 10201604757R A SG10201604757R A SG 10201604757RA SG 10201604757R A SG10201604757R A SG 10201604757RA SG 10201604757R A SG10201604757R A SG 10201604757RA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- dosing regimens
- fabry disease
- fabry
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01062—Glycosylceramidase (3.2.1.62)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161451798P | 2011-03-11 | 2011-03-11 | |
| US201161578201P | 2011-12-20 | 2011-12-20 | |
| US201261596165P | 2012-02-07 | 2012-02-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201604757RA true SG10201604757RA (en) | 2016-08-30 |
Family
ID=46831259
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013067954A SG193379A1 (en) | 2011-03-11 | 2012-03-08 | Dosing regimens for the treatment of fabry disease |
| SG10201604757RA SG10201604757RA (en) | 2011-03-11 | 2012-03-08 | Dosing regimens for the treatment of fabry disease |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013067954A SG193379A1 (en) | 2011-03-11 | 2012-03-08 | Dosing regimens for the treatment of fabry disease |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US20140219986A1 (en) |
| EP (2) | EP2683382B1 (en) |
| JP (5) | JP2014528901A (en) |
| KR (1) | KR20140011367A (en) |
| CN (2) | CN107088225A (en) |
| AU (5) | AU2012229330B2 (en) |
| CA (1) | CA2829947C (en) |
| CL (1) | CL2013002601A1 (en) |
| EA (1) | EA031874B1 (en) |
| ES (1) | ES2807502T3 (en) |
| HK (1) | HK1242998A1 (en) |
| MX (1) | MX2013010446A (en) |
| SG (2) | SG193379A1 (en) |
| TW (3) | TW201740945A (en) |
| WO (1) | WO2012125402A2 (en) |
| ZA (1) | ZA201306735B (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2533050T6 (en) | 2006-05-16 | 2015-09-21 | Amicus Therapeutics Inc | Treatment options for Fabry's disease |
| HUE051377T2 (en) | 2008-02-12 | 2021-03-01 | Amicus Therapeutics Inc | Method to predict response to pharmacological chaperone treatment of diseases |
| UY34317A (en) | 2011-09-12 | 2013-02-28 | Genzyme Corp | T cell antireceptor antibody (alpha) / ß |
| BR112015020885A2 (en) | 2013-03-11 | 2017-10-10 | Genzyme Corp | hyperglycosylated binding polypeptides |
| AU2015216909B2 (en) * | 2014-02-17 | 2017-07-20 | Glaxosmithkline Intellectual Property Development Limited | Microbiological process |
| EP3129067B1 (en) | 2014-03-19 | 2023-01-04 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
| US9675627B2 (en) * | 2014-04-14 | 2017-06-13 | Amicus Therapeutics, Inc. | Dosing regimens for treating and/or preventing cerebral amyloidoses |
| GB201508025D0 (en) * | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| JP7001593B2 (en) | 2015-08-11 | 2022-01-19 | コグノア， インコーポレイテッド | Methods and devices for determining developmental progress using artificial intelligence and user input |
| US11972336B2 (en) | 2015-12-18 | 2024-04-30 | Cognoa, Inc. | Machine learning platform and system for data analysis |
| EP3432882B1 (en) * | 2016-03-22 | 2021-09-01 | Amicus Therapeutics, Inc. | Methods of treating fabry disease in patients having the g9331a mutation in the gla gene |
| US20190183869A1 (en) * | 2016-07-19 | 2019-06-20 | Amicus Therapeutics, Inc. | Treatment of fabry disease in ert-naïve and ert-experienced patients |
| CA3053245A1 (en) | 2017-02-09 | 2018-08-16 | Cognoa, Inc. | Platform and system for digital personalized medicine |
| EP4324522A2 (en) * | 2017-05-30 | 2024-02-21 | Amicus Therapeutics, Inc. | Methods of treating fabry patients having renal impairment |
| KR102631805B1 (en) | 2017-05-30 | 2024-01-31 | 아미쿠스 세라퓨틱스, 인코포레이티드 | How to Treat Fabry Patients with Kidney Damage |
| JP7066157B2 (en) | 2017-06-14 | 2022-05-13 | 学校法人 明治薬科大学 | Combinations of drugs for the treatment of Fabry disease and their use |
| KR20200128676A (en) | 2018-02-06 | 2020-11-16 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Use of Migalastat for the treatment of Fabry disease in pregnant patients |
| US20210315875A1 (en) * | 2018-08-20 | 2021-10-14 | Amicus Therapeutics, Inc. | Methods of Treating Fabry Disease in Patients Having a Mutation in the GLA Gene |
| JP2022527946A (en) | 2019-03-22 | 2022-06-07 | コグノア，インク． | Personalized digital treatment methods and devices |
| CA3141226A1 (en) * | 2019-06-11 | 2020-12-17 | Franklin Johnson | Methods of treating fabry disease in patients having renal impairment |
| US11833164B2 (en) | 2019-08-07 | 2023-12-05 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| ES2686775T3 (en) * | 2003-01-31 | 2018-10-19 | Mount Sinai School Of Medicine Of New York University | Combination therapy to treat protein deficiency disorders |
| CN100457106C (en) * | 2005-06-15 | 2009-02-04 | 同济大学 | Use of 1-deoxynojirimycin for preparing diabete and disney disease drug |
| DK2533050T6 (en) * | 2006-05-16 | 2015-09-21 | Amicus Therapeutics Inc | Treatment options for Fabry's disease |
| CA2682441A1 (en) * | 2007-03-30 | 2008-10-09 | Amicus Therapeutics, Inc. | Method for the treatment of fabry disease using pharmacological chaperones |
| EP2150254A4 (en) * | 2007-04-26 | 2010-11-10 | Amicus Therapeutics Inc | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| WO2009032171A1 (en) * | 2007-08-29 | 2009-03-12 | Shire Human Genetic Therapies, Inc. | Subcutaneous administration of alpha-galatosidase a |
-
2012
- 2012-03-08 SG SG2013067954A patent/SG193379A1/en unknown
- 2012-03-08 US US14/004,335 patent/US20140219986A1/en not_active Abandoned
- 2012-03-08 CN CN201611235913.7A patent/CN107088225A/en active Pending
- 2012-03-08 EA EA201301018A patent/EA031874B1/en not_active IP Right Cessation
- 2012-03-08 AU AU2012229330A patent/AU2012229330B2/en active Active
- 2012-03-08 EP EP12758017.3A patent/EP2683382B1/en active Active
- 2012-03-08 EP EP20160164.8A patent/EP3698792A1/en active Pending
- 2012-03-08 JP JP2013557862A patent/JP2014528901A/en active Pending
- 2012-03-08 MX MX2013010446A patent/MX2013010446A/en unknown
- 2012-03-08 CA CA2829947A patent/CA2829947C/en active Active
- 2012-03-08 WO PCT/US2012/028260 patent/WO2012125402A2/en active Application Filing
- 2012-03-08 ES ES12758017T patent/ES2807502T3/en active Active
- 2012-03-08 CN CN201280021877.8A patent/CN103974619B/en active Active
- 2012-03-08 SG SG10201604757RA patent/SG10201604757RA/en unknown
- 2012-03-08 KR KR1020137026394A patent/KR20140011367A/en not_active Application Discontinuation
- 2012-03-12 TW TW106126844A patent/TW201740945A/en unknown
- 2012-03-12 TW TW101108345A patent/TWI624258B/en not_active IP Right Cessation
- 2012-03-12 TW TW105118425A patent/TWI624259B/en not_active IP Right Cessation
-
2013
- 2013-09-09 ZA ZA2013/06735A patent/ZA201306735B/en unknown
- 2013-09-10 CL CL2013002601A patent/CL2013002601A1/en unknown
-
2016
- 2016-06-28 AU AU2016204445A patent/AU2016204445B2/en active Active
-
2017
- 2017-03-01 JP JP2017038469A patent/JP2017132780A/en active Pending
- 2017-10-12 US US15/782,431 patent/US20180153999A1/en not_active Abandoned
-
2018
- 2018-02-23 HK HK18102615.1A patent/HK1242998A1/en unknown
- 2018-03-07 AU AU2018201637A patent/AU2018201637A1/en not_active Abandoned
-
2019
- 2019-10-10 JP JP2019186952A patent/JP2020033360A/en active Pending
-
2020
- 2020-03-02 US US16/806,404 patent/US20200268890A1/en not_active Abandoned
- 2020-03-09 AU AU2020201715A patent/AU2020201715A1/en not_active Abandoned
-
2021
- 2021-02-08 JP JP2021018456A patent/JP2021098697A/en not_active Withdrawn
-
2022
- 2022-05-05 AU AU2022203011A patent/AU2022203011A1/en active Pending
-
2023
- 2023-03-22 JP JP2023045001A patent/JP2023093448A/en active Pending
- 2023-07-17 US US18/222,745 patent/US20240115708A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1242998A1 (en) | Dosing regimens for the treatment of fabry disease | |
| PT2844279T (en) | Dosing regimens for the treatment of pompe disease | |
| ZA201403795B (en) | Formulations for the treatment of diabetes | |
| HK1201828A1 (en) | Treatment regimens using multiple pharmaceutical agents | |
| EP2673286A4 (en) | Therapeutic compounds | |
| GB201114212D0 (en) | Therapeutic agents | |
| GB201119401D0 (en) | Therapeutic agents | |
| ZA201306613B (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
| IL229081A0 (en) | Isoxazolines as therapeutic agents | |
| EP2700429A4 (en) | Drug solution applicator | |
| ZA201307760B (en) | Treatment regimens | |
| ZA201308176B (en) | Therapeutic treatment | |
| EP2687212A4 (en) | Medicament | |
| IL234796B (en) | Compounds for the treatment of ischemia-reperfusion-related diseases | |
| HK1196953A1 (en) | Formulations for the treatment of diabetes | |
| GB201106981D0 (en) | Compounds for the treatment of clostridium difficle-associated disease | |
| GB201110895D0 (en) | Therapeutic use | |
| GB201117026D0 (en) | Non-invasive monitor | |
| GB201115558D0 (en) | Therapeutic agents | |
| GB201110614D0 (en) | Therapeutic agents | |
| GB201101128D0 (en) | Therapeutic agents |